Accepted Manuscript Title: Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron Author: Jorge E Toblli Federico Di Gennaro Carlos Rivas PII: DOI: Reference:
S1443-9506(15)00034-7 http://dx.doi.org/doi:10.1016/j.hlc.2014.12.161 HLC 1768
To appear in: Received date: Revised date: Accepted date:
17-9-2014 23-12-2014 26-12-2014
Please cite this article as: Toblli JE, Di Gennaro F, Rivas C, Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron, Heart, Lung and Circulation (2015), http://dx.doi.org/10.1016/j.hlc.2014.12.161 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron
Institution (work performed): Hospital Alemán, School of Medicine,
ip t
Authors: Jorge E Toblli, Federico Di Gennaro, Carlos Rivas
us
Corresponding author Jorge E Toblli MD, PhD, FASN.
cr
University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina
an
Department of Internal Medicine, Hospital Alemán, School of Medicine,
University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina
M
Email:
[email protected] Phone: (+54 11) 4827 7000
te
d
Fax: (+54 11) 4805 6087
Ac ce p
Running title: Iron and ECHO findings in HF and CKD.
1
Page 1 of 27
Abstract Background: Treatment of iron deficiency helps to improve cardiac and renal function in patients with chronic heart failure. However, the mechanism by which this occurs is currently
ip t
unclear. Methods: We undertook a double-blind, randomised, placebo-controlled study of intravenous
cr
iron sucrose treatment (200 mg/mL weekly for five weeks) in patients with chronic heart
failure, chronic kidney disease and iron-deficiency anaemia receiving optimal treatment for
us
chronic heart failure (N=60). Markers of disease severity, iron status, anaemia and
an
inflammation were measured during a six-month follow-up period, and evaluation of echocardiographic parameters was performed at baseline and six months after treatment.
M
Results: At six months after treatment initiation, intravenous iron was associated with reduced severity of the symptoms of chronic heart failure and improved renal function (both
d
p